ESBATech

SBATech was founded in 1998. The company successfully developed its proprietary antibody fragment technology, which has been used in several clinical trials. In 2009, ESBATech was acquired by Alcon, the world leader in ophthalmology. Since Alcon only acquired the ophthalmic rights of ESBATech, a demerger at the time of acquisition was performed and all non-ophthalmic rights were transferred to Delenex Therapeutics which from then on independently further develops all previous activities of ESBATech outside of ophthalmology. In 2010, Alcon was fully acquired by Novartis and ESBATech became a Novartis company. Today it is part of the Ophthalmology Disease Area of the Novartis Institutes for BioMedical Research and responsible for research and development using single-chain antibody fragments from discovery up to clinical Proof-of-Concept.